MTNB - Earnings call transcript Q1 2019 | Matinas BioPharma Holdings, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings and welcome to the Matinas BioPharma Quarterly Update Conference Call and Webcast. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jenene Thomas with Investor Relations. you. Thank

begin. may You

Jenene Thomas

listeners Good or BioPharma and and and quarterly I are intentions, and remind this Jessy. call statements during joining state forward-looking of may webcast. you the the uncertainties. time, management's our to like Matinas update beliefs, would risks remarks morning, you, made thank this expectations everyone hopes, for At that projections Thank involve conference These call future.

provisions pursuant statements Matinas federal of this actual Harbor are materially. the Forward-looking statements BioPharma's on differ and the made laws. based to forward-looking on expectations These results securities could Safe call are current

a As should reliance undue on place any result, statements. you forward-looking not

statements BioPharma These documents actual Securities Securities to could review section and Exchange Some of Commission. from that you filed and carefully. these the website. Company's the Exchange encourage in available the differ results of factors and periodic to reports discussed the with are website in We such the documents Matinas those Investors the cause forward-looking are materially contemplated Commission's by on

call Company's be remarks, the question-and-answer will the Following a opened up session. prepared for

Development Medical Joining Dr. Executive Officer; to turn Chief Jabbour, to me Terry over today Jerry. Chief Officer. the Terry Kucinski, Ferguson, Matkovits, now on Jerry Dr. Chief Keith my pleasure call are Officer; Chief Financial is and Officer; It the call

Jerry Jabbour

well-respected all institutional to of all financing our a to start fundamental by in Good successful by call am dialed since Jenene. progress the investors. $XX of with recently those we extremely Highlighted healthcare million I you, pleased morning have led Thank XXXX. million the today. made

driver. products intently Across of exciting our we and team organization, areas into now simply, working and advance actively only well-positioned are with We potential best-in-class execution, that assets on of prescription Put extending our our believe cash to XXXX. runway role diligently We all can a asset during focused is our omega-X make into is within acid class And the MATXXXX, we quarter to and first lead XXXX. in rapidly strongly forward in landscape developing advancing value Investor a call to April fatty believe tremendous its clinical profile believe to our since strategy the world platform few a highlights moving able which few are review The Call, out take progress a our minutes technology. period MATXXXX the we've Despite this omega-X Xnd relatively of assume MATXXXX to important our our demonstrate studies. be the evolving. cardiovascular important LNC I through leadership a short well-positioned and of been we differentiated time a it's drugs. two is are

an have we of we As indication on for MATXXXX treatment advancing initial hypertriglyceridemia. calls, are aggressively outlined previous toward severe the

to foundation the development with of meeting expect half first following occur study in opportunity to as additional as which these talk with bridging provide of and the data course, of omega-X clinical strength conduct millions AstraZeneca of upon the with potentially under Of study, Epanova trial population. profile by generated conducted to MATXXXX affordable PK of Based the a are for being well ongoing could given Vascepa, growth positioned and preliminary a highly to patients. XXXBX drugs of laying FDA strong an much of a our data address believe larger comparative the reduced option tolerated, review a and therapeutic by cardiovascular FDA a that we to class tens end outcomes streamlined in patient phase the feedback X for be MATXXXX we effective XXXX. its the the We pathway, plan

with every to We triglyceride patients levels above, similar trials omega-X XXX of approved very the with in study currently and conducted X drug. one will conduct design single phase of

our those XXXX. been approval also for we an in also recently studies head-to-head are our study enough commencement Having program, planned to stronger against a to our well-established have initiate of treat having drug. the severe two ready and in Fundamentally bioavailability an focused We early conducting leading risk. differentiated believe Vascepa conducting reactivated supply MATXXXX also increased hypertriglyceridemia will for across parallel enhanced up strategy we in all coming involves IND studies months, cardiovascular required to studies now which actively biomarkers and of of potential secured best-in-class preparing to studies and conduct on are and that those variety profile efficacy X additional the the beginning for to the our phase of clear highlight important

we We readout are commence time look of as period in data our and lead made providing great these additional have to with from progress of updates studies forward and following short the a proud then trials. these compound,

designed generated the amphotericin upon our tolerated historically We administered announced to MATXXXX has Dr. RN of LNC of which the of will investigator and we without pursuing orally medicine currently the amphotericin. made MATXXXX which the cryptococcal our an Minnesota. and on last LNC his potential NIH highlight diligently amphotericin our now we serious where only conference deadly is based a for upon and amphotericin meningitis Boulware MATXXXX at toxicity administration. the disease the effective working and indication internal team technology. treat professor have well life-threatening have infectious continued that infectious standard administration. internal with lead a meningitis, bioavailable seen is platform with oral few protocol B data ID of the preclinical had deadly the care alongside Now of such Boulware NIH, relating that potent disease as orally studies. as financial our to Dr. an only IV against the formulation infection toxicity With two phases by cryptococcal a Utilizing believe most a principal platform their during a guidance, David based demonstrate are fungal now impressive brain our this severe activity division B with significant on key been we call for clinical its fungal B, is to of infections. lead support drug usually is Our we IV MATXXXX, of drug technology, University of

our We program for meeting will face-to-face protocol be of the end June. discussing this MATXXXX overall and FDA development a in set with for

efficacy the of to highly become meeting, late cryptococcal the the all and our to the be unmet drug are and degree phase well-established is variety in amphotericin we be challenging anticipate our need of for prepare patients materials significant important B quite the especially meningitis we sending this suffering and and in successful in the of in protocol of to details B, As looking this invasive interest given XXXX. expert We demonstrating position of high, we following choice MATXXXX efficacy If we could now in that medical full program of for study and meeting, within we'll for battling share profile globally. believe this FDA infections. the commencing meeting this optimism and given this physicians tolerability very deadly in forward for from population QX, study, we will of our historical are a and individuals well-tolerated of oral amphotericin FDA a fungal patient X

is key broad nervous believe platform of technology, and viability to was applicability continue also that the generating successful of data a indicator delivery the of MATXXXX including to treat system. central our We disease potentially LNC potential the

platform. an Now our on update delivery on LNC to

challenges are this we space. know, intracellular different delivery, play you As molecules, in positioning role to of technology a a in including gene those with meaningful variety solving the significant hopefully therapy

company. for our leveraging of platform are key LNT area an We additional as focus the

limiting generate on the Our verticals, programs significant be create traditional taking of broadly burdens through without funding and would for full strategic diluted variety like non see risk. is need drug We on to delivery financial drug and partnered a development solutions to this of the goal clinical technology how applied can ultimate improved while development. to capitalize

company with their hope focus. reminder, a our substantial the this of technology in their evaluation to and of As drive XX therapies in gene their in we to announced Strategically, utilize January. design global financial first a expertise top area pharmaceutical large forward we resources

meaningful areas site rapidly in which the have the efforts our finish toward ongoing data in We with protein injection toxicity oral molecules. developing utilizing very discussions expression unique number mitigating the hope their a a Each in these parties of in platform valued LNC following solution such additional technology becoming RNA to provider important could as in messenger in advancing have be administration. interested delivery of space. months, this to of area. discussions to and with our on line application our while internal continue We increasing We coming remain focused also the

demonstrate our our companies challenges very delivery We numerous polymers, unifying value forward are achieve continue continue and in about to of over opportunities the nucleic understand pleased eager to for and assets we and with potential beyond the the I more monitor, the of many this of to driving potential course to two progress to with am here. and look operating acid space, learn best-in-class milestones. a associated XXXX challenge

second Exchange mention our ring event. York Conrad in just time Xth, May invited This to that celebrated to over a distinguished years very a Matinas by was we Herb Before is I should bell. team Chairman opening unusual. honored over New important be our closing, Monday led ago which little on Stock an The two was week so the

short are appropriate speaks a of have the especially his impact in recently very pharmaceutical opening a bell. was investor and opportunity Herb It the proud first period of the and Herb over accomplished course had made upon we industry all career. of this has Matinas in time. the of We honor to the was significant very ringing that it believe

not in a could become and platform targeted the we key next potential which in and objective From cells to will to delivery a on of of royalties are choose by binary area us We say puts non want this unique believe a pleased MATXXXX, is until enviable them believe differentiation. well from to and the cash look in vision. financial making the Matinas advantage for with progress effectively perspective, choice for side for can continue I Matinas drive benefit solution is I including forward year delivery platform points our a milestones that material we and these specific multi-billion genetic on deliver to we will guidance data announcements give development closing, strategic in And based destructive our From potentially fortunate The to and turn dollar clear to the key and partner. non-toxic potential fees, approval into listeners a that that a in stress the ours. date, to drug clinical funded led that we tissues. in collect investment. partner potential breadth the fusogenic with few delivery for In in our products collaboration We to remain position of protect Matinas and and cells we well-established to of have we delivery way best-in-class and a licensing designed the then a way. our potential Matinas have execution drug of XXXX a market is his cardiovascular through to upon a are and use MATXXXX, all is of am application plan molecules, that development of XXXX. to during now company each through XXXX months. Advancing well

lie organization employees of you about our optimistic for the to enthusiastic Directors entire now over the to joining is energized, I the Thank each facilitate future individual which our ahead. our session. will our and opportunities operator and to Board Our experienced question-and-answer turn call from today. of

Operator

BTIG. of with [Operator first proceed your question. Please with the comes Instructions] line question Our from Robert Hazlett

RobertHazlett

for you questioning. on the lines taking question Two Thank the congratulations Jerry the and of and crew. progress

potential for a bit First could might June some of Just FDA? about little come of XXXX with what MATXXXX? your the more you be all, of helpful. color rapid are out setting? the Is advancement expectations would talk in of for And meeting what bit a there there little

JerryJabbour

really of excited good for essentially high We're is this survive. this area only that without meeting not because to but Sure. really this operating patients for FDA, in really help about is who focus are physicians a tool an area

it's pretty so unique this to meeting, where from in unique population all to the design. that moving And getting standard us patients. our patient through the it's protocol trial really buy-in And to that's current therapeutic its MATXXXX dealing on design a unique using is first then chances which result. with the and improve then level sure right in a pretty about [buy-in] really of where this all induction of going it's at into is of PK combination highly make instance as we detail, A get a you're their is too we're risk cohort dose much head this a get order getting becomes data of mortality to an pretty in on because as about protocol. this eventually a therapy. to Without high. And patient that's the therapy initial extremely the And step-down into designed population care of

life really patients and to balance exposing get therapies drug to our chance give save is that a their So access right which them finding important. that to between continue ensuring they to

We they're already think in --we area. this So buy-in. this that enthusiastic is with about that meeting know FDA

any protocol because to a itself, on you up or And And point we we're really here. could don't so bring the population patient expect there development. good dealing we super challenges with orphan real be streamline opportunities do but think a questions

into or believe of our these things. this ways B hope pivotal could that so there this in we trial. are is it's cohorts, can registration of a a on lot itself of cut and out generated demonstrate kind We this also amphotericin should and success protocol streamline actually XXXXfor an population positioning and historical we and patient we will in is XXXbX position of early in transition data a to already almost also that by rely which emergent development lot But

enrollment unique So that's where around and is will patient into a about had there's of our challenge. thing lot of design population Obviously, mindset going a be to study other this conducted because not it which that but needs this. be be dialogue the that, will this

today is full patients which We of are clinic going no to unfortunately option. a good who have

a So with that will can This be patient their enrollment with to where cohort to would studying faced rapidly unlike a to four move one-way to example. deadly uniform in expect without drugs in a cohort faced have the not lot are trial fashion years you three roll for infection here. that's years, or new a of relatively companies wait example a who we in from would core a population take trial enrolled having for of to case

of interest is other increasing in the the So aspect FDA and platform. our meeting with their

is exposing to older, highly efficacious ability FDA but great and highly a take to should interest potential toxic because a drugs alternative. unique them Our drugs toxic make option of patients be drugs for to patients last

bacterial MATXXXX not discussions So what aspect also for oral we our And have be what which to treat NTM our up to hope anti-infective the on potential future us a also infection. there discussions be with infections could discuss sets platform but second and like further would only including will gram-negative drug which them. aminoglycoside chronic we the first

well. as FDA for learning it's So

RobertHazlett

additional contemplates like ability endpoint I the or into And there to before long-term the --is just more a of something just bit great is color. endpoint move study side. a manufacturing But endpoint the in contemplating. little follow-up or design you're is a color what That's terms it is one something where XX-day quick

JerryJabbour

Yes.

when time. about it's these really not So studies, to you're defined talking

studies go. in for to drug cryptococcal wait that a is until When is these about long will month. utilization up about of how the we're So a of thinking meningitis, kind to we be that FDA who go amphotericin talk to there your use into going likely of expectation experiencing you're patient

these way of of therapy with will induction being be our balanced with But and that not because of our a fungal nephrotoxicity. formulation intrigued use irreversible cost you're this with implications the care with is of the MATXXXX, So in because deadly of use the of Patterson about drug out using will to is days than IBM so but way really only administration chronic then structured, is XX that initially, and study thing without XX starting you But long-term combination available any or inconvenience looking it right it XX-days but of it a you're eventually not standard at in the that not lot there the unique patients. what everyone longer looking because IV has can't at infection, --the readily and flip. see and

magic and protocol this for So demonstrate no that But be can there's able around oral is designed to XX-days. to of period be tolerated. XXXX time used our longer a be well

RobertHazlett

that's you helpful. term able of if could so, some Any manufacturing be Okay, very longer XXXX. light if shed in in the place And would in XXXX strategies for be clinical additional color on thinking and helpful. to the that being manufacturing studies through general there any terms gave on

JerryJabbour

plan to Sure. we're hopefully and because patients. a where get we think we about It's large be we we be lot to to going a amount believe of supply something can position ahead in an indication able

a But supply on suppliers available forward position chain, to go be in you key a your We kind of two X also about or you're mission the to you short our and one intermediates suppliers And so pretty for put the on which then not to currently want role. year that quickly. So capsule reliant ensuring And obviously, which a time, with plan same them critical begin secured really able Phase think that we that have as a expand chain, the plays we of was a we it's product these And there for and in will we're half evolution are different us could happy time. aspects together. and to period have chain. passage our supply are in our of variety essentially bring as of that supply of is technology supply just good. buy time then we've a studies proprietary

final XXmonths, and you whether your an our bring you you board. supply would of next already of we an things. be and believe will so right And couple and talking the are And of to same a technology or with for expect will of that So specs over removes lessening omega-X to your on of we're creates about we mitigating working risk using we're suppliers I've we and capsule any that cost are -- the does in area Obviously, formulation the it supply does suppliers with it interruption. XX additional get over-reliance, important to additional redundancy other MATXXXX this identified and And the that improve important. goods. continue the gives thing cost give then it in opportunity goods to chain the very

goods I that drug think general of endeavor a time, having our there theirs is of with cost is pay our the over other be that to will which really is is recognition space, inexpensive going At time we is same an volumes omega-X highly this cost will that the as a improve price goods purity for the line recognized not refined players higher you of high goods. increase. and cost just like important your in in improve

So of clinical of will launch exactly to together eventually are move when those be too other as confident project of goods upon land where but with commercialization. products be, come we will omega-X in through forecasts, in terms say goods cost begin approved line we and we put our further. we will the our will down what It's cost even we to development early

Operator

Our comes Isaacson proceed your Jerry question. Please from Capital. with next the with line ROTH question of

UnidentifiedAnalyst

Isaacson. Ana for This on Jerry is Hi.

color so like it had around a other of a mentioned. it around color which bit could little of for If you what and just maybe seems than indications used? bit the of be give give And could could expert applications the you. lot a and Thank little there's technology be platform that other different LNC just you

JerryJabbour

Sure.

them these lymphocytes of So unique unique these are any about also delivered even these delivery and because nano get that you're nanoparticles because Typically, them cells, put to and puts activated to be by make the ability oral up orally up One, seen the there or which and a then taken bioavailable. position. a composition particles must of taken of particles the few the you by when technology bioavailability traditional ability to take stability simply if get cells. We've intravenously. can adenovirus a of has of molecule, and of get unique monocytes thinking technologies something deliver using in method pretty very sorts like drug, molecules lipid it encapsulated

we cells there for or of to And point And and we and particles of small hydrophobic large the really to small Number deliver. key like amikacin, differentiation large be about ability CRISPR drugs everything essentially really plasmids, large get what makes flexibility way can to kilobases. about and hydrophilic all or and the dendritic the have DNA able example think think you cells of is then attracted to I'm cells are it lipid about fact nano being the That's for like our that we and that of unique the disease talking strategies about to in So molecules, are has with into way deliver we traditional a to to XX like player that molecules. and that we are with. the bilayer you the for in is excited the antivirals. NIH orally. the we area. from -- are intracellular the too have us Those identified formulation we macrophage applications and large have the become type two cells that a ability with doing flexible attracted our particles can amphotericin one. are work way which Those molecules to number trap flexibility these because in molecules molecules and lipid key to shown work up They're

which you small And take about them ability think really, getting and because existing We're drugs cell is or exactly example preclinical do messenger inside it believe get that our in we're when so response. far you way RNA we which that in we really of generating challenge directly get these make how we immune disease our getting greater immune destruction is We do can at so thing. drug into twofold. work, actually genetic passing to very is least hides, animal and XX% drug macrophages important, more SPOT, an like do the do the antiviral it's encapsulate then protect without And the delivering safely can the than not for be any that's a potent we yield when where interfering drugs that we've from the and differentiator. then important intact how And you a material. molecules then One what right models in exciting. unintended which RNA, material to an really, response. it's really genetic And delivering seen a without generating get a

to it's about them models the our technology. stable hope can and we store room of oral immunogenicity take molecules, continue formulations, animal to Taking lack And the that to And to that is collaboration oligonucleotide even those we RNA under or demonstrate area early where the of companies pleased these a those area And it's announced into and in proof temperature, from who in wanting so ability more concept. messenger about want areas administration. discussion where and then players giving first in like really antivirals major creating today we expression demonstrating or the with following learn protein play. at the areas whether interest their to collaborations in are other we're

taking in for example unique large an that's the us solution out are a out of I obviously there the disease in and eliminate drug to tissues blood it number of to take with drug in areas. us ability cells a blood-borne are keep our we amphotericin. blood Because not example. and for does mean ideal So allows for make what of toxicity then

that board uniform delivery that. does we play on are weaknesses to it companies every capitalize want experiencing with the for drug, solution it's some and So strengths across our to the but

UnidentifiedAnalyst

give the see some on where question the so you. funds the is you second .And this my primary taking in Thank you use wondered quarter. the thank of has I much color financing on you of could based that activity Great, first if company. happened some

JerryJabbour

question. for the you Thank

obviously, the the change we're institutional to it thrilled with of company So, world. perception within Vivo the It the Capital. led begins healthcare financing just-- by

And Vascepa so firm that essentially our our and years no main our focus clear the financing us that this but was and of from use proceeds for it's of two transaction, limitation use it money There in proceeds gives to is takes with runway. latest of raised we us study meeting September in It read through of then drive of against interesting MATXXXX really and end an a XXXX. work we head-to-head forward. August beginning to or round X Phase essentially this which expect the will out

of resourced from Health we pay the continues to our program. in National really Big So for that the luxury the this well and is MATXXXX have designed Institutes have for money who a a and luxury we is Brother have we

fact And are layer interest. areas you on of NIH's six the side that to on Pharma's across concept, strategy every have luxury advancing resort an in then to that coming without to interest three the ago you business forego months. of into fundraisings it the dollar do the made driving capital at the when the to to choice the a didn't our have dilute because multi-billion and expense And a market. prove we the platform in we having all dollars the from years now to make so order of having forward investors of And another from Big of sustainable the asset gives MATXXXX we well-funded

platform non and So of utilizing capitalized our are the we we're MATXXXX our well resources partners to the drive dilutive then federal now, cash forward government the resources drive to and forward.

UnidentifiedAnalyst

Vascepa was about talk I going you to the for Great you and mentioned Matinas? the it pivot could its had trajectory and now Vascepa wondering the just been in can -- XQ I'm mean increase that hasn't off as what expected and Amarin just from of

JerryJabbour

focused high is It's them dose more FDA but patients looking believe interaction and will an we a it XX on reduce you it's give XX the high the country. the and in they're revolutionary almost label about which do great a market. Amarin to lot with map. freedom omega-X purity expanding when or question. We're noticing on label of the And to expand their intently to the have Obviously, we omega to the it the data nature now same work million transformational think their this puts really promote drug on forward to trends

resonate the six months, with not the I'm over course starting they've the data that see So that surprised of you're generated last to physicians.

because has and what and are going physicians to uptick pharma perfect as in more development, then this who a in bigger advancing to want. is changing them that's because get expanding to a as fact Now Ameren be be out XXX% big add literally This there is looking will to physician give that in up a the this you safe setting a XXXX. And big bodes to it's study the there more And a storm for up is as data profile prescribing good It's takes had are to behavior we almost outcome been a exactly and us. you as quarter-over-quarter. Matinas their time pharma this that well top AstraZeneca out the the for which data on patient read all statin and from gives drug their exposed of to opportunity drug market. going

to continue generates. prescriptions Vascepa we the that will So monitor

a such data that for the we from but a monitor We greatest a strength they're trial, be as time in forward in to omega-X us up mission on $X continue to to the and designed growing studies these and way differentiation, MATXXXX million set the best-in-class think to will but start will approval prescription look designed product in an to come market, to that to prescription in ensuring million $XXX our soon position demonstrate not is now continue to way billion $XXX such $X and we billion important market. to

of for have the the plowing they're that we road so to us gone And before now is We Q&A timing get the the learn on advantage, perfect. the take on to path. development commercialization path. companies from us get End And

Operator

you. Thank

this And participation. lines and teleconference. you this for we your session. may end at the reached time. Ladies today's does question-and-answer have And gentlemen, conclude We thank your of you disconnect our

Matinas BioPharma (MTNB) 14 May 192019 Q1 Earnings call transcript